SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,011,609 | -45.6% | 69,670 | -21.6% | 0.00% | -100.0% |
| Q2 2023 | $1,860,614 | +40.0% | 88,897 | +41.3% | 0.00% | – |
| Q1 2023 | $1,328,955 | +928.9% | 62,924 | +1139.9% | 0.00% | – |
| Q4 2022 | $129,159 | -24.0% | 5,075 | -28.2% | 0.00% | – |
| Q3 2022 | $170,000 | +39.3% | 7,072 | +10.6% | 0.00% | – |
| Q2 2022 | $122,000 | -38.4% | 6,395 | -43.9% | 0.00% | – |
| Q1 2022 | $198,000 | -65.4% | 11,394 | -56.4% | 0.00% | – |
| Q4 2021 | $572,000 | +450.0% | 26,162 | +379.9% | 0.00% | – |
| Q3 2021 | $104,000 | +10.6% | 5,451 | 0.0% | 0.00% | – |
| Q2 2021 | $94,000 | -57.1% | 5,451 | -44.7% | 0.00% | – |
| Q1 2021 | $219,000 | -84.1% | 9,855 | -84.1% | 0.00% | – |
| Q4 2020 | $1,380,000 | +49.0% | 62,105 | -1.1% | 0.00% | – |
| Q3 2020 | $926,000 | -28.3% | 62,775 | -28.1% | 0.00% | – |
| Q2 2020 | $1,292,000 | +378.5% | 87,285 | +254.5% | 0.00% | – |
| Q1 2020 | $270,000 | -49.1% | 24,625 | -59.1% | 0.00% | – |
| Q4 2019 | $530,000 | +157.3% | 60,280 | +117.5% | 0.00% | – |
| Q3 2019 | $206,000 | -43.6% | 27,712 | -29.4% | 0.00% | – |
| Q2 2019 | $365,000 | +45.4% | 39,237 | -17.9% | 0.00% | – |
| Q1 2019 | $251,000 | +30.7% | 47,772 | +11.1% | 0.00% | – |
| Q4 2018 | $192,000 | +53.6% | 42,989 | +177.1% | 0.00% | – |
| Q3 2018 | $125,000 | +64.5% | 15,512 | +44.2% | 0.00% | – |
| Q2 2018 | $76,000 | -47.9% | 10,756 | +4.4% | 0.00% | – |
| Q1 2018 | $146,000 | +80.2% | 10,300 | +11.2% | 0.00% | – |
| Q4 2017 | $81,000 | -2.4% | 9,261 | +31.6% | 0.00% | – |
| Q3 2017 | $83,000 | +260.9% | 7,037 | +327.0% | 0.00% | – |
| Q2 2017 | $23,000 | 0.0% | 1,648 | 0.0% | 0.00% | – |
| Q1 2017 | $23,000 | +91.7% | 1,648 | 0.0% | 0.00% | – |
| Q4 2016 | $12,000 | -52.0% | 1,648 | 0.0% | 0.00% | – |
| Q3 2016 | $25,000 | – | 1,648 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |